These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35793110)

  • 21. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
    Martin RM; Turner EL; Young GJ; Metcalfe C; Walsh EI; Lane JA; Sterne JAC; Noble S; Holding P; Ben-Shlomo Y; Williams NJ; Pashayan N; Bui MN; Albertsen PC; Seibert TM; Zietman AL; Oxley J; Adolfsson J; Mason MD; Davey Smith G; Neal DE; Hamdy FC; Donovan JL;
    JAMA; 2024 May; 331(17):1460-1470. PubMed ID: 38581198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer.
    Orczyk C; Barratt D; Brew-Graves C; Peng Hu Y; Freeman A; McCartan N; Potyka I; Ramachandran N; Rodell R; Williams NR; Emberton M; Ahmed HU
    J Urol; 2021 Apr; 205(4):1090-1099. PubMed ID: 33315505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Focal irreversible electroporation as primary treatment for localized prostate cancer.
    van den Bos W; Scheltema MJ; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
    BJU Int; 2018 May; 121(5):716-724. PubMed ID: 28796935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Focal Therapy of Prostate Cancer Index Lesion With Irreversible Electroporation. A Prospective Study With a Median Follow-up of 3 Years.
    Miñana López B; Andrés Boville G; Barbas Bernardos G; Ancizu Marckert X; Torres Roca M; Labairu Huerta L; Villacampa Aubá F; Ramón de Fata Chillón F; Sanz Ortega J; Abengózar Muela M; Gallardo Madueño G; Benito Boíllos A; Alcázar Peral A; Díez-Caballero Alonso F
    J Urol; 2023 Jan; 209(1):261-270. PubMed ID: 36073928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation.
    Scheltema MJ; Chang JI; van den Bos W; Böhm M; Delprado W; Gielchinsky I; de Reijke TM; de la Rosette JJ; Siriwardana AR; Shnier R; Stricker PD
    Eur Urol Focus; 2019 Jul; 5(4):585-591. PubMed ID: 29102671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years.
    Bahn D; de Castro Abreu AL; Gill IS; Hung AJ; Silverman P; Gross ME; Lieskovsky G; Ukimura O
    Eur Urol; 2012 Jul; 62(1):55-63. PubMed ID: 22445223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
    Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
    Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial.
    Ghai S; Perlis N; Lindner U; Hlasny E; Haider MA; Finelli A; Zlotta AR; Kulkarni GS; van der Kwast TH; McCluskey SA; Kucharczyk W; Trachtenberg J
    Eur Radiol; 2018 Oct; 28(10):4281-4287. PubMed ID: 29696431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.
    Grossfeld GD; Latini DM; Lubeck DP; Mehta SS; Carroll PR
    J Urol; 2003 Jan; 169(1):157-63. PubMed ID: 12478126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer: A Secondary Analysis of 2 Randomized Clinical Trials.
    King MT; Chen MH; Collette L; Neven A; Bolla M; D'Amico AV
    JAMA Netw Open; 2021 May; 4(5):e2111092. PubMed ID: 33999161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes.
    Feijoo ER; Sivaraman A; Barret E; Sanchez-Salas R; Galiano M; Rozet F; Prapotnich D; Cathala N; Mombet A; Cathelineau X
    Eur Urol; 2016 Feb; 69(2):214-20. PubMed ID: 26164416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer.
    Zhang K; Stricker P; Löhr M; Stehling M; Suberville M; Cussenot O; Lunelli L; Ng CF; Teoh J; Laguna P; de la Rosette J
    Prostate Cancer Prostatic Dis; 2024 Sep; 27(3):525-530. PubMed ID: 38195916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Magnetic resonance image-guided focal laser ablation in clinically localized prostate cancer: safety and efficacy.
    Al-Hakeem Y; Raz O; Gacs Z; Maclean F; Varol C
    ANZ J Surg; 2019 Dec; 89(12):1610-1614. PubMed ID: 31679182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiation therapy and IRreversible electroporation for intermediate risk prostate cancer (RTIRE).
    Diven M; Ballman K; Marciscano A; Barbieri C; Piscopo J; Wang S; Nagar H; McClure T
    BMC Urol; 2024 Jul; 24(1):151. PubMed ID: 39054460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
    Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW
    J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomes.
    Qaoud Y; Herrera-Caceres JO; Bass R; Berjaoui MB; Tiwari R; Kenk M; Lajkosz K; Finelli A; Perlis N; Klotz L; Fleshner N
    Urol Oncol; 2022 Jul; 40(7):343.e1-343.e6. PubMed ID: 35537905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.